Coherus Highlights Results from the P-II Study of Casdozokitug for Advanced or Metastatic Hepatocellular Carcinoma (uHCC)
Shots:
- The P-II study assesses the safety and tolerability of casdozokitug (10mg/kg, IV, Q3W) + atezolizumab (1200 mg) & bevacizumab (15mg/kg) in patients (n=30) with treatment-naïve unresectable locally advanced/metastatic hepatocellular carcinoma (uHCC)
- The results, as of Nov 9, 2023, showed an ORR of 38% (n=29), with 11 durable objective responses (3 CRs and 8 PRs), mPFS was 8.1mos. & DCR was 58.6%, based on RECIST v1.1 criteria. Another analysis showed an ORR of 43% (n=28), with 12 durable objective responses (3 CRs and 9 PRs), mPFS was not attained & DCR was 60.7%, based on mRECIST
- Casdozokitug is a FIC human anti-IL-27 antibody that targets the activity of the immunosuppressive cytokine
Ref: Coherus | Image: Coherus
Related News:- Coherus and Junshi Biosciences Received the US FDA’s Approval for Loqtorzi (toripalimab-tpzi) to Treat Nasopharyngeal Carcinoma (NPC)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.
